Update on cyclooxygenase-2 inhibitors.

Harris RC, Breyer MD
Clin J Am Soc Nephrol. 2006 1 (2): 236-45

PMID: 17699212 · DOI:10.2215/CJN.00890805

Nonsteroidal anti-inflammatory drugs represent the most commonly used medications for the treatment of pain and inflammation, but numerous well-described side effects can limit their use. Cyclooxygenase-2 (COX-2) inhibitors were initially touted as a therapeutic strategy to avoid not only the gastrointestinal but also the renal and cardiovascular side effects of nonspecific nonsteroidal anti-inflammatory drugs. However, in the kidney, COX-2 is constitutively expressed and is highly regulated in response to alterations in intravascular volume. COX-2 metabolites have been implicated in mediation of renin release, regulation of sodium excretion, and maintenance of renal blood flow. This review summarizes the current state of knowledge about both renal and cardiovascular side effects that are attributed to COX-2 selective inhibitors.

MeSH Terms (10)

Animals Blood Pressure Cardiovascular Physiological Phenomena Cyclooxygenase 2 Inhibitors Homeostasis Humans Kidney Proteinuria Renin Water-Electrolyte Balance

Connections (2)

This publication is referenced by other Labnodes entities: